REVIEW article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1608140
This article is part of the Research TopicInnovations in Biomarker-Based Lung Cancer ScreeningView all 11 articles
The Multifaceted Roles of Mucins Family in Lung Cancer: From Prognostic Biomarkers to Promising Targets
Provisionally accepted
- 1Department of Immunology, Fourth Military Medical University, Xi’an, China
- 2The Key Laboratory of Bio-Hazard Damage and Prevention Medicine, Basic Medicine School, Air-Force Medical University (The Fourth Military Medical University), Xi’an 710032, China, China
- 3Department of Rehabilitation Medicine, Tangdu Hospital, the Fourth Military Medical University, Xi'an, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Lung cancer remains one of the leading causes of cancer-related deaths worldwide, highlighting the urgent need for enhanced diagnostic and therapeutic strategies. Mucins, a family of glycoproteins crucial for maintaining epithelial integrity and regulating immune responses, have emerged as promising biomarkers and therapeutic targets in the context of lung cancer. The expression patterns and functional roles of mucin family members significantly influence lung cancer progression, thereby shaping diagnostic and therapeutic approaches for this disease. A more detailed classification of mucin family members could facilitate diagnosis and patient assessments, as well as help identify potential therapeutic targets. This review thoroughly examines the latest advancements in understanding the role of mucins in lung cancer progression, prognosis, and treatment, while also highlighting knowledge gaps and opportunities for future research, thus providing new perspectives for the management of this disease.
Keywords: Mucins, lung cancer, biomarkers, targets, prognosis, Therapeutics
Received: 08 Apr 2025; Accepted: 16 Jun 2025.
Copyright: © 2025 Yuan, Cai, Chang, Zhang, Wang, Yang and Jiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Kun Yang, Department of Immunology, Fourth Military Medical University, Xi’an, China
Dongbo Jiang, Department of Immunology, Fourth Military Medical University, Xi’an, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.